Dayan Goodenowe, the founder of the contentious Dr. Goodenowe Restorative Health Center, disclosed plans for establishing a drug manufacturing lab and clinical trials center in Moose Jaw, Saskatchewan. These initiatives are part of his vision for a “health revolution” focused on eradicating Alzheimer’s disease. Goodenowe shared his aspirations during an event held at a luxurious golf and spa resort in southern California on February 13. His associate introduced him as a remarkable figure, likening him to a superhero and a “disease Pokémon hunter” for his innovative technology.
During his address, Goodenowe asserted his belief that Alzheimer’s is conquerable, emphasizing insights from his book, “Breaking Alzheimer’s: A 15 Year Crusade to Expose the Cause and Deliver the Cure.” He emphasized the importance of identifying and overcoming obstacles hindering the implementation of an Alzheimer’s eradication program. Goodenowe also promoted his Elite Practitioner Program, urging attendees to join and be part of a groundbreaking treatment approach set to become a global standard.
Central to Goodenowe’s plan is his supplement, ProdromeNeuro, which he aims to develop into an FDA-approved drug for Alzheimer’s treatment. The supplement will be produced at his pharmaceutical facility and tested at the clinical trials center in Moose Jaw. Goodenowe expressed confidence in obtaining full FDA approval by 2029 and criticized delays caused by past events, such as the disruption of his previous company, Phenomenome Discoveries Inc. (PDI).
Despite Goodenowe’s ambitious claims and initiatives, skepticism surrounds his track record and credibility, with former associates questioning his veracity. Issues regarding the unauthorized use of ProdromeNeuro in clinical studies and previous controversies have drawn regulatory scrutiny and media attention. Furthermore, legal battles, investigations, and financial challenges have plagued Goodenowe’s ventures, raising doubts about his leadership and business practices.